Patents by Inventor Hai Yan

Hai Yan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10705935
    Abstract: A method and system for generating a job alert. According to embodiments of the present invention, before a target job is processed, a characteristic of input and output of the target job in at least one stage is determined through analyzing a historical job, and a resource overhead associated with the processing of the target job is calculated based on the characteristic of input and output. Then, an alert for the target job is generated in response to the resource overhead exceeding a predetermined threshold. In such manner, an alert for the target job can be proactively generated before the resource overhead problem occurs, so as to enable an administrator or developer to discover a fault in advance and adopt measures actively to avoid loss and damage to the intermediate results or output data when the target job is processed.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: July 7, 2020
    Assignee: INTERNATIONAL BUSINESS MACHINES CORPORATION
    Inventors: Zhao Cao, Peng Li, Jun Ma, Ju Wei Shi, Bing Jiang Sun, Chen Wang, Lin Hao Xu, Chang Hai Yan, Xiao Ning Zhang, Jia Zou
  • Publication number: 20200190197
    Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Programmed Death Ligand-1 (PD-L1). These PD-L1 antibodies, or antigen-binding fragments thereof, have a high affinity for PD-L1, function to inhibit PD-L1, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human), are capable of increasing T-cell proliferation and IL-2 secretion in a mixed lymphocyte reaction, and can be used to treat human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).
    Type: Application
    Filed: December 23, 2017
    Publication date: June 18, 2020
    Inventors: Frank J. Calzone, Hai Yan, John Zhang
  • Patent number: 10633711
    Abstract: Methods that rapidly, sensitively, and specifically detect mutations in IDH1/2 and the TERT promoter employ amplification of particular portions of the genes that experience frequent and exquisitely localized mutations. The ability to distinguish between sequences that differ only by one nucleotide and which may be present in very low ratios is essential for such an assay.
    Type: Grant
    Filed: August 24, 2015
    Date of Patent: April 28, 2020
    Assignee: Duke University
    Inventors: Hai Yan, Yiping He, Rui Yang, Bill H. Diplas, Landon Hansen, Darell Bigner
  • Patent number: 10626179
    Abstract: The present disclosure relates to methods for treating type 1 diabetes (T1D) using a glucagon receptor blocking agent. More specifically, the present disclosure relates to methods for treating T1D using substantially lower doses of insulin supplementation, or even in the absence of insulin supplementation, using antigen binding and antagonizing proteins, e.g., fully human antibodies that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Grant
    Filed: June 8, 2015
    Date of Patent: April 21, 2020
    Assignee: REMD Biotherapeutics, Inc.
    Inventors: Hai Yan, Jim Shi
  • Patent number: 10619217
    Abstract: Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: April 14, 2020
    Assignees: The Johns Hopkins University, Duke University
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Chetan Bettegowda, Nishant Agrawal, Nickolas Papadopoulos, Darell Bigner, Hai Yan, Roger McLendon
  • Patent number: 10604797
    Abstract: Many areas of biomedical research depend on the analysis of uncommon variations in individual genes or transcripts. Here we describe a method that can quantify such variation at a scale and ease heretofore unattainable. Each DNA molecule in a collection of such molecules is converted into a single particle to which thousands of copies of DNA identical in sequence to the original are bound. This population of beads then corresponds to a one-to-one representation of the starting DNA molecules. Variation within the original population of DNA molecules can then be simply assessed by counting fluorescently-labeled particles via flow cytometry Millions of individual DNA molecules can be assessed in this fashion with standard laboratory equipment. Moreover, specific variants can be isolated by flow sorting and employed for further experimentation.
    Type: Grant
    Filed: April 12, 2016
    Date of Patent: March 31, 2020
    Assignee: The Johns Hopkins University
    Inventors: Devin Dressman, Hai Yan, Kenneth W. Kinzler, Bert Vogelstein
  • Patent number: 10571627
    Abstract: An optical fiber comprises, from a center to a periphery, a fiber core of undoped silica; a cladding layer; and a coating of polyacrylate, wherein the fiber core has a radius of 5 to 7 ?m and an ellipticity of less than 1.5%, the cladding layer with an ellipticity of less than 0.4% comprises inner, intermediate, and outer cladding layers, the inner cladding layer being doped with fluorine of 5 to 12 ?m thickness, and refractive index difference to fiber core of ?0.4 to ?0.2%, the outer cladding layer being undoped quartz of 25 to 45 ?m thickness, and the coating comprises an inner coating of 25 to 40 ?m thickness, and an outer coating of 25 to 35 ?m thickness and an ellipticity of less than 2%. The optical fiber has high durability and large effective transmission area, a method and system for preparing such optical fiber are also disclosed.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: February 25, 2020
    Assignees: ZHONGTIAN TECHNOLOGY FIBER POTICS CO., LTD, ZHONGTIAN TECHNOLOGY ADVANCED MATERIALS CO., LTD., JIANGSU ZHONGTIAN TECHNOLOGY CO., LTD.
    Inventors: Shan-Shan Cao, Zhi-Zhong Liu, Yi-Chun Shen, Xiao-Xing Zhu, Zhen Wang, Hai-Tao Zhang, Hai-Tao Xu, Ji-Gang Hu, Hai-Yan Su
  • Publication number: 20200055937
    Abstract: This application provides, inter alia, antibodies or antigen-binding fragments thereof, targeting CTLA-4 expressed on injured tissues associated with multiple diseases. These anti-CTLA-4 antibodies, or antigen-binding fragments thereof, have a high affinity for CTLA-4 and function to inhibit CTLA-4. The antibodies and antigen-binding fragments are useful for treatment of human diseases, infections, and other conditions.
    Type: Application
    Filed: January 5, 2018
    Publication date: February 20, 2020
    Inventors: Frank J Calzone, Hai Yan
  • Publication number: 20190352711
    Abstract: The present invention discloses a method for rapidly constructing amplicon library including the following steps: 1. Synthesizing a primer combination for constructing an amplicon library of a DNA sample, the primer combination of the amplicon library used to construct the DNA sample includes: an upstream fusion primer designed according to the target amplicon, a downstream fusion primer designed according to the target amplicon, an upstream universal primer and a downstream universal primer; 2. Constructing a PCR reaction system for the DNA sample; 3. Performing PCR. The method according to the present invention can be used to construct an amplicon library in a simple and rapid manner, and since a barcode is introduced before the start of PCR, the possibility of cross-contamination between the sample and the library is greatly reduced.
    Type: Application
    Filed: March 28, 2018
    Publication date: November 21, 2019
    Inventors: Hai Yan, Sizhen Wang, Yuchen Jiao, Dayong Xu, Qiaosong Zheng, Xiao Shi
  • Publication number: 20190330346
    Abstract: This application provides isolated antibodies, and antigen-binding fragments thereof, that specifically bind Programmed Death 1 (PD-1). These PD-1 antibodies, or antigen-binding fragments thereof, have a high affinity for PD-1, function to inhibit PD-1, are less immunogenic compared to their unmodified parent antibodies in a given species (e.g., a human), are capable of increasing T-cell proliferation and IL-2 secretion in a mixed lymphocyte reaction, and can be used to treat human diseases (e.g., cancer, infectious diseases, autoimmune diseases, asthma, transplant rejection, and inflammatory disorders).
    Type: Application
    Filed: December 23, 2017
    Publication date: October 31, 2019
    Inventors: Frank J Calzone, Hai Yan, John Zhang
  • Publication number: 20190106752
    Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
    Type: Application
    Filed: September 17, 2018
    Publication date: April 11, 2019
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
  • Publication number: 20190101693
    Abstract: An optical fiber comprises, from a center to a periphery, a fiber core of undoped silica; a cladding layer; and a coating of polyacrylate, wherein the fiber core has a radius of 5 to 7 ?m and an ellipticity of less than 1.5%, the cladding layer with an ellipticity of less than 0.4% comprises inner, intermediate, and outer cladding layers, the inner cladding layer being doped with fluorine of 5 to 12 ?m thickness, and refractive index difference to fiber core of ?0.4 to ?0.2%, the outer cladding layer being undoped quartz of 25 to 45 ?m thickness, and the coating comprises an inner coating of 25 to 40 ?m thickness, and an outer coating of 25 to 35 ?m thickness and an ellipticity of less than 2%. The optical fiber has high durability and large effective transmission area, a method and system for preparing such optical fiber are also disclosed.
    Type: Application
    Filed: November 30, 2018
    Publication date: April 4, 2019
    Inventors: SHAN-SHAN CAO, ZHI-ZHONG LIU, YI-CHUN SHEN, XIAO-XING ZHU, ZHEN WANG, HAI-TAO ZHANG, HAI-TAO XU, JI-GANG HU, HAI-YAN SU
  • Publication number: 20190062441
    Abstract: The present disclosure relates to methods for treating various rare genetic disorders which are characterized, in part, by abnormal resistance to insulin and/or hyperglycemia using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating a rare genetic disorder using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Application
    Filed: October 6, 2016
    Publication date: February 28, 2019
    Inventors: Hai Yan, Jeong Oh
  • Publication number: 20190002577
    Abstract: The present invention relates to methods of treating Type 2 diabetes (T2D), comprising administering to a patient an effective amount of an isolated antagonistic antigen binding protein that specifically binds to the human glucagon receptor, either as monotherapy, or in combination with one or more antidiabetic medications.
    Type: Application
    Filed: January 4, 2017
    Publication date: January 3, 2019
    Applicant: REMD Biotherapeutics, Inc.
    Inventors: Jim Shi, Hai Yan
  • Patent number: 10154213
    Abstract: An imaging sensor may include an array of imaging pixels and at least two rows of dark pixels. Each imaging pixel may include a photodiode that generates charge in response to incident light. Each dark pixel may include a photodiode that is shielded from incident light by shielding material. The at least two rows of dark pixels may be sampled simultaneously and averaged to obtain an average dark pixel charge level. The average dark pixel charge level may be subtracted from each imaging pixel charge level to correct the imaging pixel charge levels for noise. Each column of dark pixels may include a column line that is coupled to first and second readout circuits. Each column line may be coupled to first and second current sources. Each column line may be coupled to at least one capacitor.
    Type: Grant
    Filed: September 28, 2016
    Date of Patent: December 11, 2018
    Assignee: SEMICONDUCTOR COMPONENTS INDUSTRIES, LLC
    Inventor: Hai Yan
  • Publication number: 20180334726
    Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.
    Type: Application
    Filed: May 25, 2018
    Publication date: November 22, 2018
    Inventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao
  • Publication number: 20180282821
    Abstract: We found mutations of the R132 residue of isocitrate dehydrogenase 1 (IDH1) in the majority of grade II and III astrocytomas and oligodendrogliomas as well as in gliblastomas that develop from these lower grade lesions. Those tumors without mutations in IDH1 often had mutations at the analogous R172 residue of the closely related IDH2 gene. These findings have important implications for the pathogenesis and diagnosis of malignant gliomas.
    Type: Application
    Filed: March 22, 2018
    Publication date: October 4, 2018
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, D. Williams Parsons, Xiaosong Zhang, Jimmy Cheng-Ho Lin, Rebecca J. Leary, Philipp Angenendt, Nickolas Papadopoulos, Victor Velculescu, Giovanni Parmigiani, Rachel Karchin, Sian Jones, Hai Yan, Darell Bigner, Chien-Tsun Kuan, Gregory J. Riggins
  • Publication number: 20180256713
    Abstract: The present disclosure relates to methods for treating or preventing heart failure using a glucagon receptor blocking agent. In various embodiments, the present disclosure relates to methods for treating or preventing heart failure (e.g., post-myocardial infarction heart failure), diabetic cardiomyopathy heart failure), and lateral ventricular (LV) remodeling, using antigen binding and antagonizing proteins, e.g., fully human antibodies, that specifically bind to and antagonize the function of the human glucagon receptor.
    Type: Application
    Filed: September 2, 2016
    Publication date: September 13, 2018
    Inventor: Hai Yan
  • Publication number: 20180195132
    Abstract: Oligodendrogliomas are the second most common malignant brain tumor in adults. These tumors often contain a chromosomal abnormality involving a pericentromeric fusion of chromosomes 1 and 19, resulting in losses of the entire short arm of the former and the long arm of the latter. To identify the molecular genetic basis for this alteration, we performed exomic sequencing of seven anaplastic oligodendrogliomas with chromosome 1p and 19q losses. Among other changes, we found that that CIC (homolog of the Drosophila gene capicua) on chromosome 19q was somatically mutated in six of the seven cases and that FUBP1 (far upstream element (FUSE) binding protein) on chromosome 1p was somatically mutated in two of the seven cases. Examination of 27 additional oligodendrogliomas revealed 12 and 3 more tumors with mutations of CIC and FUBP1, respectively, 58% of which were predicted to result in truncations of the encoded proteins.
    Type: Application
    Filed: December 7, 2017
    Publication date: July 12, 2018
    Inventors: Bert Vogelstein, Kenneth W. Kinzler, Chetan Bettegowda, Nishant Agrawal, Nickolas Papadopoulos, Darell Bigner, Hai Yan, Roger McLendon
  • Patent number: 9982306
    Abstract: We determined the sequence of ATRX and DAXX in 447 cancers from various sites. We found mutations most commonly in pediatric glioblastoma multiformae (GBM) (11.1%), adult GBM (6.5%), oligodendrogliomas (7.7%) and medulloblastomas (1.5%); and showed that Alternative Lengthening of Telomeres (ALT), a telomerase-independent telomere maintenance mechanism found in cancers that have not activated telomerase, perfectly correlated with somatic mutations of either gene. In contrast, neuroblastomas, and adenocarcinomas of the ovary, breast, and pancreas were negative for mutations in ATRX and DAXX. Alterations in ATRX or DAXX define a specific molecular pathway that is closely associated with an alternative telomere maintenance function in human cancers.
    Type: Grant
    Filed: June 28, 2012
    Date of Patent: May 29, 2018
    Assignees: Duke University, The Johns Hopkins University
    Inventors: Hai Yan, Darell Bigner, Bert Vogelstein, Kenneth W. Kinzler, Alan Meeker, Ralph Hruban, Nickolas Papadopoulos, Luis Diaz, Yuchen Jiao